Related Experiment Video

Updated: Nov 19, 2025

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.6K

Hypertension in cancer patients treated with anti-angiogenic based regimens

Yishay Wasserstrum1,2, Ran Kornowski1,2, Pia Raanani3,2

  • 1Department of Cardiology, Rabin Medical Center, Petah Tikva, 49100, Israel.

Cardio-Oncology (London, England)
|February 3, 2021
PubMed

Insights

New anti-cancer drugs targeting the vascular endothelial growth factor (VEGF) pathway are effective but can cause hypertension. This review covers the incidence, mechanisms, and management of this common side effect in cancer patients.

Area of Science:

  • Oncology
  • Cardiovascular Pharmacology

Background:

  • Vascular endothelial growth factor (VEGF) signaling pathway inhibitors are crucial in treating solid tumors.
  • Cardiovascular safety concerns, particularly hypertension, are associated with VEGF pathway inhibition.

Purpose of the Study:

  • To review the incidence, mechanisms, significance, and management of hypertension in patients receiving VEGF pathway inhibitors.

Main Methods:

  • Literature review of studies on VEGF inhibitors and hypertension.
  • Analysis of reported incidence rates and proposed pathophysiological mechanisms.
  • Evaluation of clinical significance and current management strategies.

Main Results:

  • Hypertension is the most frequent side effect of VEGF signaling pathway (VSP) inhibitors.
  • Multiple mechanisms contribute to VSP inhibitor-induced hypertension.
  • Effective management strategies are available to mitigate this cardiovascular risk.

Conclusions:

  • VEGF pathway inhibitors offer significant anti-cancer benefits but require careful cardiovascular monitoring.
  • Understanding and managing treatment-emergent hypertension is essential for patient safety and treatment adherence.
  • Further research into personalized management of hypertension in VSP inhibitor-treated patients is warranted.
Keywords:
CardiotoxicityHypertensionTyrosine kinase inhibitorVEGFVEGF signal pathway inhibitorsVSP inhibitorsVascular endothelial growth factor

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

10.0K
A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics12:09

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

Published on: June 16, 2013

11.8K

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
313
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
160
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
283